Movement Alert｜EVEREST MED Falls 5.03% in Regular Trading, Pullback Follows Earlier mRNA Talent-Hire Rally

Market Focus10-14

On October 14, EVEREST MED fell 5.03% in Regular Trading, trading at HK$31.36, with turnover of HK$86.80 million.

The most recent market-moving context points to a pullback after the stock had rallied in the prior two sessions on news that the company hired two former Moderna scientists to accelerate global clinical development of its mRNA platform.

Earlier disclosures said the new executives would focus on US clinical development and related business expansion for EVEREST MED's mRNA platform, while coordinating with the China R&D team. Supporting background includes interim revenue of RMB1.148 billion, up 157.3%, with attributable loss narrowed to RMB5.94 million. The latest price weakness appears tied to fading short-term event momentum rather than a newly disclosed negative catalyst.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment